封面
市場調查報告書
商品編碼
2177379

14-α-去甲基酶抑制劑市場:全球市場預測,2026-2032年

14-Alpha Demethylase Inhibitor Market - Global Forecast 2026-2032

出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年,14-α-去甲基轉移酶抑制劑市場規模將達到 18.9 億美元,複合年成長率為 4.84%。

主要市場統計數據
基準年 2025 13.5億美元
預計年份:2026年 14.3億美元
預測年份 2032 18.9億美元
複合年成長率 (%) 4.84%

14-α-去甲基轉移酶抑制劑:概述

14-α-去甲基酶抑制劑是一類抗真菌藥物,它們透過抑制麥角固醇的生物合成來削弱真菌細胞膜。這類藥物在人類醫學、獸醫學和作物保護領域都具有重要意義,但不同領域的監管環境、核准用途和證據標準差異顯著。該市場的發展受到感染疾病負擔、抗藥性管理、產品安全性、製劑性能和合理使用要求等因素的影響。

正在重塑抗真菌藥物研發和使用方式的變革

目前的趨勢是從依賴現有的唑類化合物轉向更具針對性、基於實證醫學的治療策略。關鍵變化包括更加關注唑類抗藥性菌株、聯合治療療法和序貫療法、改進給藥系統、提高藥物的環境持久性以及更嚴格地評估交叉抗藥性。在農業領域,綜合蟲害管理(IPM)方案更著重作物輪作、遵守標籤檢視和非化學防治,而不是反覆使用單一作用機制的殺蟲劑。

人工智慧可以促進藥物發現、監測和合理使用。

人工智慧可以透過對候選分子進行優先排序、預測結合和毒性訊號、分析敏感性數據以及識別與治療失敗相關的模式來支持該領域的研究。它還可以促進診斷影像、抗藥性監測、製劑最佳化和農業病害監測的改進。然而,由於生物變異性和監測不完整可能導致誤導性結果,​​因此有效實施仍需要檢驗的資料集、透明的模型評估、實驗室驗證、隱私保護和人工監督。

六大主要區域的區域洞察

在北美,臨床合理用藥、抗藥性監測和監管證據是重點。同時,拉丁美洲面臨農業領域的巨大需求,但醫療保健資源和監管能力方面也存在差距。歐洲高度重視抗菌藥物的合理使用、環境評估和協調監管。中東面臨著獲取途徑不均、氣候變遷帶來的農業壓力以及對具有韌性的分銷系統的需求。非洲的優先事項包括診斷能力、可負擔性、供應連續性和作物保護的可近性。亞太地區的需求多種多樣,包括先進的監測系統、大規模的農業部門、感染疾病控制以及各國標準不一等。

世界各區域的集團層級優先事項

東協市場需要靈活的註冊、分銷和合理使用方法,以反映其多樣化的醫療保健系統和農業實踐。金磚國家成員國擁有大規模的研發、生產和農業能力,但監管差異也很大,因此互通性和證據共用至關重要。歐盟專注於評估、環境保護措施和抗藥性控制的協調統一。七國集團(G7)國家普遍優先考慮先進的診斷技術、產品品質和上市後監管。海灣合作理事會(GCC)國家重視進口韌性、臨床應用和在糧食安全領域的應用,而北約成員國則受惠於針對衛生安全風險的協調準備和供應鏈規劃。

國家層級的策略規劃趨勢

澳洲優先考慮農業領域的生物安全、抗藥性管理和監管。巴西在滿足重大作物保護需求的同時,也擁有大規模的醫療保健體系,因此非常重視藥物註冊和合理使用。加拿大優先考慮抗菌藥物的合理使用、環境評估以及分散人口的可及性。中國和印度在生產製造、農業應用、國內研究以及不斷發展的法律規範都扮演著重要角色。日本和韓國則專注於高品質的臨床證據、先進的製劑以及技術驅動的監測。法國、德國、義大利和西班牙在歐洲監管和管理框架內運作,特別關注醫療保健品質和永續農業。英國優先考慮其醫療保健系統中的獨立監管審查、抗菌藥物抗性監測和管理。墨西哥面臨著平衡農業生產力、醫療保健可及性和監管一致性的挑戰。俄羅斯的情況則受到其國家生產目標、農業需求以及不斷變化的准入條件的影響。美國尤其重視臨床證據、抗藥性監測、產品安全和綜合蟲害管理。

抗真菌藥物創新領域產業領導者指南

領導者在建構產品系列,不應僅著眼於新穎性,而應關注差異化的作用機制、更佳的耐受性、可操作的製劑以及在抗藥性管理方面的價值。他們還應制定符合各國法規的合規計劃,投資於經驗檢驗的藥敏試驗和診斷能力,並根據需要在臨床、獸醫、農業和環境領域積累證據。與實驗室、醫療系統、生產商和公共機構夥伴關係,可以加強監管和合理用藥管理。數位化和人工智慧工具應透過具有明確績效標準的受控試點計畫引入,同時,供應鏈冗餘、品管系統和透明的環境評估仍應是營運重點。

調查方法執行摘要

本概要基於所提供的市場範圍(14-α-去甲基酶抑制劑),按應用、技術、法規、地區和相關人員對分析進行組織。對已確立的特性(例如麥角甾醇生物合成抑制、抗真菌藥物抗藥性、合理使用、診斷、製劑開發和區域政策環境)的見解進行了定性總結。本概要不包含市場估算、預測、市場佔有率或公司層級的聲明。國家和群體特定觀察結果僅作為策略背景提供,在實際應用前應根據當前的監管決策、臨床指南、監測記錄和當地農業法規進行檢驗。

結論:透過證據、管理和韌性來贏得競爭。

目前,14-α-去甲基酶抑制劑的現狀呈現出一種矛盾的局面:一方面,人們仍然需要有效控制真菌;另一方面,人們又日益重視藥物的安全性、抗藥性抑制、環境責任以及可靠的獲取途徑。永續發展取決於差異化的科學研究、更可靠的診斷方法、協調一致的監測以及在人類健康和農業領域的規範使用。那些能夠將創新與本地監管知識、負責任的管理以及穩健的供應計劃相結合的機構,將更有能力應對不斷變化的生物學和政策環境。

目錄

第1章:序言

第2章:調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章:人工智慧的累積影響,2026年

第7章:14-α-去甲基酶抑制劑市場:依藥物類型分類

  • 咪唑衍生物
    • Clotrimazole
    • Ketoconazole
    • Miconazole
  • 三唑
    • Fluconazole
    • Itraconazole
    • Voriconazole

第8章:14-α-去甲基酶抑制劑市場:依給藥途徑分類

  • 靜脈
  • 口服
    • 膠囊
    • 懸浮液
    • 藥片
  • 外用
    • 奶油
    • 凝膠
    • 軟膏

第9章:14-α-去甲基酶抑制劑市場:依應用領域分類

  • 皮膚感染疾病
    • 念珠菌症
    • 灰指甲
    • 香港腳
  • 預防
    • 免疫力缺乏患者
    • 手術預防
  • 全身性行為感染
    • 麴菌症
    • 念珠菌血症
    • 隱球菌病

第10章:14-α-去甲基酶抑制劑市場:依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章:14-α-去甲基酶抑制劑市場:按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章:14-α-去甲基酶抑制劑市場:依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章:14-α-去甲基酶抑制劑市場:依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析,2025年
    • 濃度比(CR)
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析,2025 年
  • 2025年產品系列分析
  • 基準分析,2025 年

第15章:公司簡介

  • AbbVie Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mycovia Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

第16章 主要專家

Product Code: MRR-4772A753A24C

The 14-Alpha Demethylase Inhibitor Market is projected to grow by USD 1.89 billion at a CAGR of 4.84% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.35 billion
Estimated Year [2026] USD 1.43 billion
Forecast Year [2032] USD 1.89 billion
CAGR (%) 4.84%

14-Alpha Demethylase Inhibitors: Executive Overview

14-alpha demethylase inhibitors are antifungal agents that disrupt ergosterol biosynthesis, weakening fungal cell membranes. Their relevance spans human medicine, veterinary applications, and crop protection, although regulatory status, approved uses, and evidence standards differ substantially across these settings. The market is shaped by infection burden, resistance management, product safety, formulation performance, and stewardship requirements.

Shifts Reshaping Antifungal Development and Use

The landscape is moving from reliance on established azole chemistry toward more targeted, evidence-led treatment strategies. Important shifts include greater attention to azole-resistant organisms, combination or sequential therapy, improved delivery systems, environmental persistence, and tighter evaluation of cross-resistance. In agriculture, integrated pest-management programs are increasing the emphasis on rotation, label compliance, and nonchemical controls rather than repeated use of a single mode of action.

Artificial Intelligence Strengthens Discovery, Surveillance, and Stewardship

Artificial intelligence can support this field by prioritizing molecular candidates, predicting binding and toxicity signals, analyzing susceptibility data, and identifying patterns associated with treatment failure. It can also improve image-based diagnosis, resistance surveillance, formulation optimization, and agricultural disease monitoring. Effective deployment still requires validated datasets, transparent model evaluation, laboratory confirmation, privacy safeguards, and human oversight because biological variability and incomplete surveillance can produce misleading outputs.

Regional Insights Across Six Major Geographies

North America emphasizes clinical stewardship, resistance monitoring, and regulatory evidence, while Latin America combines substantial agricultural demand with varied healthcare access and regulatory capacity. Europe places strong weight on antimicrobial stewardship, environmental assessment, and coordinated regulation. The Middle East faces uneven access, climate-linked agricultural pressures, and the need for resilient distribution systems. Africa's priorities include diagnostic capacity, affordability, supply continuity, and crop-protection access. Asia-Pacific presents diverse requirements spanning advanced research systems, large agricultural sectors, infectious-disease management, and differing national standards.

Group-Level Priorities Across Global Blocs

ASEAN markets require adaptable registration, distribution, and stewardship approaches that reflect varied health systems and agricultural practices. BRICS members combine major research, production, and farming capabilities with significant regulatory diversity, making interoperability and evidence exchange important. The European Union centers on harmonized assessment, environmental safeguards, and resistance containment. G7 economies generally prioritize advanced diagnostics, product quality, and post-market surveillance. GCC countries emphasize import resilience, clinical access, and food-security applications, while NATO members benefit from coordinated preparedness and supply-chain planning for health-security risks.

Country-Level Signals for Strategic Planning

Australia emphasizes biosecurity, resistance management, and agricultural stewardship. Brazil combines major crop-protection needs with a large healthcare system and rigorous attention to registration and responsible use. Canada prioritizes antimicrobial stewardship, environmental review, and access across dispersed populations. China and India are important for manufacturing, agricultural applications, domestic research, and evolving regulatory oversight. Japan and South Korea focus on high-quality clinical evidence, advanced formulation, and technology-enabled monitoring. France, Germany, Italy, and Spain operate within European regulatory and stewardship frameworks, with strong attention to healthcare quality and sustainable agriculture. The United Kingdom emphasizes independent regulatory review, resistance surveillance, and health-system stewardship. Mexico faces the need to balance agricultural productivity, healthcare access, and regulatory consistency. Russia's environment is shaped by domestic production objectives, agricultural requirements, and evolving access conditions. The United States places particular weight on clinical evidence, resistance surveillance, product safety, and integrated pest management.

Actions for Industry Leaders in Antifungal Innovation

Leaders should build portfolios around differentiated mechanisms, improved tolerability, practical formulations, and resistance-management value rather than novelty alone. They should establish country-specific regulatory plans, invest in validated susceptibility and diagnostic capabilities, and generate evidence across clinical, veterinary, agricultural, and environmental settings where relevant. Partnerships with laboratories, healthcare systems, growers, and public agencies can strengthen surveillance and stewardship. Digital and AI tools should be introduced through controlled pilots with clear performance thresholds, while supply-chain redundancy, quality systems, and transparent environmental assessments should remain core operating priorities.

Research Methodology for the Executive Summary

This summary uses the supplied market scope-14-alpha demethylase inhibitors-and organizes analysis across applications, technology, regulation, geography, and stakeholder groups. Insights are framed qualitatively from established characteristics of ergosterol-biosynthesis inhibition, antifungal resistance, stewardship, diagnostics, formulation development, and regional policy environments. No market estimates, forecasts, market shares, or company-level claims are included. Country and group observations are presented as strategic context and should be validated against current regulatory decisions, clinical guidance, surveillance records, and local agricultural rules before operational use.

Conclusion: Compete Through Evidence, Stewardship, and Resilience

The 14-alpha demethylase inhibitor landscape is defined by the tension between continuing need for effective fungal control and rising demands for safety, resistance containment, environmental responsibility, and reliable access. Durable progress will depend on differentiated science, stronger diagnostics, coordinated surveillance, and disciplined use across human health and agriculture. Organizations that connect innovation with regional regulatory insight, responsible stewardship, and resilient supply planning will be better positioned to address changing biological and policy conditions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. 14-Alpha Demethylase Inhibitor Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Imidazoles
    • 7.2.1. Clotrimazole
    • 7.2.2. Ketoconazole
    • 7.2.3. Miconazole
  • 7.3. Triazoles
    • 7.3.1. Fluconazole
    • 7.3.2. Itraconazole
    • 7.3.3. Voriconazole

8. 14-Alpha Demethylase Inhibitor Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
    • 8.3.1. Capsule
    • 8.3.2. Suspension
    • 8.3.3. Tablet
  • 8.4. Topical
    • 8.4.1. Cream
    • 8.4.2. Gel
    • 8.4.3. Ointment

9. 14-Alpha Demethylase Inhibitor Market, by Application

  • 9.1. Introduction
  • 9.2. Dermatological Infections
    • 9.2.1. Candidiasis
    • 9.2.2. Onychomycosis
    • 9.2.3. Tinea Pedis
  • 9.3. Prophylaxis
    • 9.3.1. Immunocompromised Patients
    • 9.3.2. Surgical Prophylaxis
  • 9.4. Systemic Infections
    • 9.4.1. Aspergillosis
    • 9.4.2. Candidemia
    • 9.4.3. Cryptococcosis

10. 14-Alpha Demethylase Inhibitor Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. 14-Alpha Demethylase Inhibitor Market, by Region

  • 11.1. Introduction
  • 11.2. Asia-Pacific
  • 11.3. North America
  • 11.4. Latin America
  • 11.5. Europe
  • 11.6. Middle East
  • 11.7. Africa

12. 14-Alpha Demethylase Inhibitor Market, by Group

  • 12.1. Introduction
  • 12.2. ASEAN
  • 12.3. GCC
  • 12.4. European Union
  • 12.5. BRICS
  • 12.6. G7
  • 12.7. NATO

13. 14-Alpha Demethylase Inhibitor Market, by Country

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. United Kingdom
  • 13.7. Germany
  • 13.8. France
  • 13.9. Russia
  • 13.10. Italy
  • 13.11. Spain
  • 13.12. China
  • 13.13. India
  • 13.14. Japan
  • 13.15. Australia
  • 13.16. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. Market Concentration Analysis, 2025
    • 14.2.1. Concentration Ratio (CR)
    • 14.2.2. Herfindahl Hirschman Index (HHI)
  • 14.3. Recent Developments & Impact Analysis, 2025
  • 14.4. Product Portfolio Analysis, 2025
  • 14.5. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. AbbVie Inc.
  • 15.2. AstraZeneca plc
  • 15.3. Bayer AG
  • 15.4. Bristol-Myers Squibb Company
  • 15.5. Eli Lilly and Company
  • 15.6. GlaxoSmithKline plc
  • 15.7. Johnson & Johnson Services, Inc.
  • 15.8. Merck & Co., Inc.
  • 15.9. Mycovia Pharmaceuticals, Inc.
  • 15.10. Novartis AG
  • 15.11. Pfizer Inc.
  • 15.12. Sanofi S.A.
  • 15.13. Sun Pharmaceutical Industries Ltd.
  • 15.14. Teva Pharmaceutical Industries Ltd.

16. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global 14-Alpha Demethylase Inhibitor Market, Years Considered for the Study
  • FIGURE 2. Global 14-Alpha Demethylase Inhibitor Market, Research Design
  • FIGURE 3. Global 14-Alpha Demethylase Inhibitor Market, Research Framework
  • FIGURE 4. Global 14-Alpha Demethylase Inhibitor Market, Data Triangulation
  • FIGURE 5. Global 14-Alpha Demethylase Inhibitor Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2025 vs 2032 (%)
  • FIGURE 7. Global 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2025 vs 2032 (%)
  • FIGURE 9. Global 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global 14-Alpha Demethylase Inhibitor Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 11. Global 14-Alpha Demethylase Inhibitor Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 13. Global 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global 14-Alpha Demethylase Inhibitor Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 15. Global 14-Alpha Demethylase Inhibitor Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global 14-Alpha Demethylase Inhibitor Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 17. Global 14-Alpha Demethylase Inhibitor Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 18. Global 14-Alpha Demethylase Inhibitor Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global 14-Alpha Demethylase Inhibitor Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global 14-Alpha Demethylase Inhibitor Market Segmentation & Coverage
  • TABLE 2. Global 14-Alpha Demethylase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 4. Global Imidazoles Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Imidazoles Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Imidazoles Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Clotrimazole Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Clotrimazole Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Clotrimazole Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Ketoconazole Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Ketoconazole Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Ketoconazole Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Miconazole Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Miconazole Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Miconazole Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Triazoles Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Triazoles Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Triazoles Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Fluconazole Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Fluconazole Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Fluconazole Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Itraconazole Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Itraconazole Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Itraconazole Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Voriconazole Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Voriconazole Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Voriconazole Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 29. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 30. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 31. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 32. Global Oral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 33. Global Oral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 34. Global Oral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 35. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 36. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 37. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 38. Global Suspension Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global Suspension Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global Suspension Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Topical Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Global Topical Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 46. Global Topical Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 47. Global Cream Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 48. Global Cream Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 49. Global Cream Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 50. Global Gel Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. Global Gel Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 52. Global Gel Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 53. Global Ointment Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Global Ointment Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 55. Global Ointment Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 56. Global 14-Alpha Demethylase Inhibitor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 57. Global Dermatological Infections Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 58. Global Dermatological Infections Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 59. Global Dermatological Infections Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 60. Global Candidiasis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 61. Global Candidiasis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 62. Global Candidiasis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 63. Global Onychomycosis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 64. Global Onychomycosis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 65. Global Onychomycosis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 66. Global Tinea Pedis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 67. Global Tinea Pedis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 68. Global Tinea Pedis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 69. Global Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 70. Global Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 71. Global Prophylaxis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 72. Global Immunocompromised Patients Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 73. Global Immunocompromised Patients Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 74. Global Immunocompromised Patients Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 75. Global Surgical Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 76. Global Surgical Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 77. Global Surgical Prophylaxis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 78. Global Systemic Infections Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 79. Global Systemic Infections Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 80. Global Systemic Infections Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 81. Global Aspergillosis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 82. Global Aspergillosis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 83. Global Aspergillosis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 84. Global Candidemia Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 85. Global Candidemia Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 86. Global Candidemia Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 87. Global Cryptococcosis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 88. Global Cryptococcosis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 89. Global Cryptococcosis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 90. Global 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 91. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 92. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 93. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 94. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 95. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 96. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 97. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 98. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 99. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 100. Global 14-Alpha Demethylase Inhibitor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 101. Asia-Pacific 14-Alpha Demethylase Inhibitor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 102. Asia-Pacific 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 103. Asia-Pacific 14-Alpha Demethylase Inhibitor Market Size, by Imidazoles, 2017-2032 (USD Million)
  • TABLE 104. Asia-Pacific 14-Alpha Demethylase Inhibitor Market Size, by Triazoles, 2017-2032 (USD Million)
  • TABLE 105. Asia-Pacific 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 106. Asia-Pacific 14-Alpha Demethylase Inhibitor Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 107. Asia-Pacific 14-Alpha Demethylase Inhibitor Market Size, by Topical, 2017-2032 (USD Million)
  • TABLE 108. Asia-Pacific 14-Alpha Demethylase Inhibitor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 109. Asia-Pacific 14-Alpha Demethylase Inhibitor Market Size, by Dermatological Infections, 2017-2032 (USD Million)
  • TABLE 110. Asia-Pacific 14-Alpha Demethylase Inhibitor Market Size, by Prophylaxis, 2017-2032 (USD Million)
  • TABLE 111. Asia-Pacific 14-Alpha Demethylase Inhibitor Market Size, by Systemic Infections, 2017-2032 (USD Million)
  • TABLE 112. Asia-Pacific 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 113. North America 14-Alpha Demethylase Inhibitor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 114. North America 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 115. North America 14-Alpha Demethylase Inhibitor Market Size, by Imidazoles, 2017-2032 (USD Million)
  • TABLE 116. North America 14-Alpha Demethylase Inhibitor Market Size, by Triazoles, 2017-2032 (USD Million)
  • TABLE 117. North America 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 118. North America 14-Alpha Demethylase Inhibitor Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 119. North America 14-Alpha Demethylase Inhibitor Market Size, by Topical, 2017-2032 (USD Million)
  • TABLE 120. North America 14-Alpha Demethylase Inhibitor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 121. North America 14-Alpha Demethylase Inhibitor Market Size, by Dermatological Infections, 2017-2032 (USD Million)
  • TABLE 122. North America 14-Alpha Demethylase Inhibitor Market Size, by Prophylaxis, 2017-2032 (USD Million)
  • TABLE 123. North America 14-Alpha Demethylase Inhibitor Market Size, by Systemic Infections, 2017-2032 (USD Million)
  • TABLE 124. North America 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 125. Latin America 14-Alpha Demethylase Inhibitor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 126. Latin America 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 127. Latin America 14-Alpha Demethylase Inhibitor Market Size, by Imidazoles, 2017-2032 (USD Million)
  • TABLE 128. Latin America 14-Alpha Demethylase Inhibitor Market Size, by Triazoles, 2017-2032 (USD Million)
  • TABLE 129. Latin America 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 130. Latin America 14-Alpha Demethylase Inhibitor Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 131. Latin America 14-Alpha Demethylase Inhibitor Market Size, by Topical, 2017-2032 (USD Million)
  • TABLE 132. Latin America 14-Alpha Demethylase Inhibitor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 133. Latin America 14-Alpha Demethylase Inhibitor Market Size, by Dermatological Infections, 2017-2032 (USD Million)
  • TABLE 134. Latin America 14-Alpha Demethylase Inhibitor Market Size, by Prophylaxis, 2017-2032 (USD Million)
  • TABLE 135. Latin America 14-Alpha Demethylase Inhibitor Market Size, by Systemic Infections, 2017-2032 (USD Million)
  • TABLE 136. Latin America 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 137. Europe 14-Alpha Demethylase Inhibitor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 138. Europe 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 139. Europe 14-Alpha Demethylase Inhibitor Market Size, by Imidazoles, 2017-2032 (USD Million)
  • TABLE 140. Europe 14-Alpha Demethylase Inhibitor Market Size, by Triazoles, 2017-2032 (USD Million)
  • TABLE 141. Europe 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 142. Europe 14-Alpha Demethylase Inhibitor Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 143. Europe 14-Alpha Demethylase Inhibitor Market Size, by Topical, 2017-2032 (USD Million)
  • TABLE 144. Europe 14-Alpha Demethylase Inhibitor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 145. Europe 14-Alpha Demethylase Inhibitor Market Size, by Dermatological Infections, 2017-2032 (USD Million)
  • TABLE 146. Europe 14-Alpha Demethylase Inhibitor Market Size, by Prophylaxis, 2017-2032 (USD Million)
  • TABLE 147. Europe 14-Alpha Demethylase Inhibitor Market Size, by Systemic Infections, 2017-2032 (USD Million)
  • TABLE 148. Europe 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 149. Middle East 14-Alpha Demethylase Inhibitor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 150. Middle East 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 151. Middle East 14-Alpha Demethylase Inhibitor Market Size, by Imidazoles, 2017-2032 (USD Million)
  • TABLE 152. Middle East 14-Alpha Demethylase Inhibitor Market Size, by Triazoles, 2017-2032 (USD Million)
  • TABLE 153. Middle East 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 154. Middle East 14-Alpha Demethylase Inhibitor Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 155. Middle East 14-Alpha Demethylase Inhibitor Market Size, by Topical, 2017-2032 (USD Million)
  • TABLE 156. Middle East 14-Alpha Demethylase Inhibitor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 157. Middle East 14-Alpha Demethylase Inhibitor Market Size, by Dermatological Infections, 2017-2032 (USD Million)
  • TABLE 158. Middle East 14-Alpha Demethylase Inhibitor Market Size, by Prophylaxis, 2017-2032 (USD Million)
  • TABLE 159. Middle East 14-Alpha Demethylase Inhibitor Market Size, by Systemic Infections, 2017-2032 (USD Million)
  • TABLE 160. Middle East 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 161. Africa 14-Alpha Demethylase Inhibitor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 162. Africa 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 163. Africa 14-Alpha Demethylase Inhibitor Market Size, by Imidazoles, 2017-2032 (USD Million)
  • TABLE 164. Africa 14-Alpha Demethylase Inhibitor Market Size, by Triazoles, 2017-2032 (USD Million)
  • TABLE 165. Africa 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 166. Africa 14-Alpha Demethylase Inhibitor Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 167. Africa 14-Alpha Demethylase Inhibitor Market Size, by Topical, 2017-2032 (USD Million)
  • TABLE 168. Africa 14-Alpha Demethylase Inhibitor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 169. Africa 14-Alpha Demethylase Inhibitor Market Size, by Dermatological Infections, 2017-2032 (USD Million)
  • TABLE 170. Africa 14-Alpha Demethylase Inhibitor Market Size, by Prophylaxis, 2017-2032 (USD Million)
  • TABLE 171. Africa 14-Alpha Demethylase Inhibitor Market Size, by Systemic Infections, 2017-2032 (USD Million)
  • TABLE 172. Africa 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 173. Global 14-Alpha Demethylase Inhibitor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 174. ASEAN 14-Alpha Demethylase Inhibitor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 175. ASEAN 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 176. ASEAN 14-Alpha Demethylase Inhibitor Market Size, by Imidazoles, 2017-2032 (USD Million)
  • TABLE 177. ASEAN 14-Alpha Demethylase Inhibitor Market Size, by Triazoles, 2017-2032 (USD Million)
  • TABLE 178. ASEAN 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 179. ASEAN 14-Alpha Demethylase Inhibitor Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 180. ASEAN 14-Alpha Demethylase Inhibitor Market Size, by Topical, 2017-2032 (USD Million)
  • TABLE 181. ASEAN 14-Alpha Demethylase Inhibitor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 182. ASEAN 14-Alpha Demethylase Inhibitor Market Size, by Dermatological Infections, 2017-2032 (USD Million)
  • TABLE 183. ASEAN 14-Alpha Demethylase Inhibitor Market Size, by Prophylaxis, 2017-2032 (USD Million)
  • TABLE 184. ASEAN 14-Alpha Demethylase Inhibitor Market Size, by Systemic Infections, 2017-2032 (USD Million)
  • TABLE 185. ASEAN 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 186. GCC 14-Alpha Demethylase Inhibitor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 187. GCC 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 188. GCC 14-Alpha Demethylase Inhibitor Market Size, by Imidazoles, 2017-2032 (USD Million)
  • TABLE 189. GCC 14-Alpha Demethylase Inhibitor Market Size, by Triazoles, 2017-2032 (USD Million)
  • TABLE 190. GCC 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 191. GCC 14-Alpha Demethylase Inhibitor Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 192. GCC 14-Alpha Demethylase Inhibitor Market Size, by Topical, 2017-2032 (USD Million)
  • TABLE 193. GCC 14-Alpha Demethylase Inhibitor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 194. GCC 14-Alpha Demethylase Inhibitor Market Size, by Dermatological Infections, 2017-2032 (USD Million)
  • TABLE 195. GCC 14-Alpha Demethylase Inhibitor Market Size, by Prophylaxis, 2017-2032 (USD Million)
  • TABLE 196. GCC 14-Alpha Demethylase Inhibitor Market Size, by Systemic Infections, 2017-2032 (USD Million)
  • TABLE 197. GCC 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 198. European Union 14-Alpha Demethylase Inhibitor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 199. European Union 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 200. European Union 14-Alpha Demethylase Inhibitor Market Size, by Imidazoles, 2017-2032 (USD Million)
  • TABLE 201. European Union 14-Alpha Demethylase Inhibitor Market Size, by Triazoles, 2017-2032 (USD Million)
  • TABLE 202. European Union 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 203. European Union 14-Alpha Demethylase Inhibitor Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 204. European Union 14-Alpha Demethylase Inhibitor Market Size, by Topical, 2017-2032 (USD Million)
  • TABLE 205. European Union 14-Alpha Demethylase Inhibitor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 206. European Union 14-Alpha Demethylase Inhibitor Market Size, by Dermatological Infections, 2017-2032 (USD Million)
  • TABLE 207. European Union 14-Alpha Demethylase Inhibitor Market Size, by Prophylaxis, 2017-2032 (USD Million)
  • TABLE 208. European Union 14-Alpha Demethylase Inhibitor Market Size, by Systemic Infections, 2017-2032 (USD Million)
  • TABLE 209. European Union 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 210. BRICS 14-Alpha Demethylase Inhibitor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 211. BRICS 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 212. BRICS 14-Alpha Demethylase Inhibitor Market Size, by Imidazoles, 2017-2032 (USD Million)
  • TABLE 213. BRICS 14-Alpha Demethylase Inhibitor Market Size, by Triazoles, 2017-2032 (USD Million)
  • TABLE 214. BRICS 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 215. BRICS 14-Alpha Demethylase Inhibitor Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 216. BRICS 14-Alpha Demethylase Inhibitor Market Size, by Topical, 2017-2032 (USD Million)
  • TABLE 217. BRICS 14-Alpha Demethylase Inhibitor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 218. BRICS 14-Alpha Demethylase Inhibitor Market Size, by Dermatological Infections, 2017-2032 (USD Million)
  • TABLE 219. BRICS 14-Alpha Demethylase Inhibitor Market Size, by Prophylaxis, 2017-2032 (USD Million)
  • TABLE 220. BRICS 14-Alpha Demethylase Inhibitor Market Size, by Systemic Infections, 2017-2032 (USD Million)
  • TABLE 221. BRICS 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 222. G7 14-Alpha Demethylase Inhibitor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 223. G7 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 224. G7 14-Alpha Demethylase Inhibitor Market Size, by Imidazoles, 2017-2032 (USD Million)
  • TABLE 225. G7 14-Alpha Demethylase Inhibitor Market Size, by Triazoles, 2017-2032 (USD Million)
  • TABLE 226. G7 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 227. G7 14-Alpha Demethylase Inhibitor Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 228. G7 14-Alpha Demethylase Inhibitor Market Size, by Topical, 2017-2032 (USD Million)
  • TABLE 229. G7 14-Alpha Demethylase Inhibitor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 230. G7 14-Alpha Demethylase Inhibitor Market Size, by Dermatological Infections, 2017-2032 (USD Million)
  • TABLE 231. G7 14-Alpha Demethylase Inhibitor Market Size, by Prophylaxis, 2017-2032 (USD Million)
  • TABLE 232. G7 14-Alpha Demethylase Inhibitor Market Size, by Systemic Infections, 2017-2032 (USD Million)
  • TABLE 233. G7 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 234. NATO 14-Alpha Demethylase Inhibitor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 235. NATO 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 236. NATO 14-Alpha Demethylase Inhibitor Market Size, by Imidazoles, 2017-2032 (USD Million)
  • TABLE 237. NATO 14-Alpha Demethylase Inhibitor Market Size, by Triazoles, 2017-2032 (USD Million)
  • TABLE 238. NATO 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 239. NATO 14-Alpha Demethylase Inhibitor Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 240. NATO 14-Alpha Demethylase Inhibitor Market Size, by Topical, 2017-2032 (USD Million)
  • TABLE 241. NATO 14-Alpha Demethylase Inhibitor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 242. NATO 14-Alpha Demethylase Inhibitor Market Size, by Dermatological Infections, 2017-2032 (USD Million)
  • TABLE 243. NATO 14-Alpha Demethylase Inhibitor Market Size, by Prophylaxis, 2017-2032 (USD Million)
  • TABLE 244. NATO 14-Alpha Demethylase Inhibitor Market Size, by Systemic Infections, 2017-2032 (USD Million)
  • TABLE 245. NATO 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 246. Global 14-Alpha Demethylase Inhibitor Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 247. United States 14-Alpha Demethylase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 248. United States 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 249. United States 14-Alpha Demethylase Inhibitor Market Size, by Imidazoles, 2017-2032 (USD Million)
  • TABLE 250. United States 14-Alpha Demethylase Inhibitor Market Size, by Triazoles, 2017-2032 (USD Million)
  • TABLE 251. United States 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 252. United States 14-Alpha Demethylase Inhibitor Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 253. United States 14-Alpha Demethylase Inhibitor Market Size, by Topical, 2017-2032 (USD Million)
  • TABLE 254. United States 14-Alpha Demethylase Inhibitor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 255. United States 14-Alpha Demethylase Inhibitor Market Size, by Dermatological Infections, 2017-2032 (USD Million)
  • TABLE 256. United States 14-Alpha Demethylase Inhibitor Market Size, by Prophylaxis, 2017-2032 (USD Million)
  • TABLE 257. United States 14-Alpha Demethylase Inhibitor Market Size, by Systemic Infections, 2017-2032 (USD Million)
  • TABLE 258. United States 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 259. Canada 14-Alpha Demethylase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 260. Canada 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 261. Canada 14-Alpha Demethylase Inhibitor Market Size, by Imidazoles, 2017-2032 (USD Million)
  • TABLE 262. Canada 14-Alpha Demethylase Inhibitor Market Size, by Triazoles, 2017-2032 (USD Million)
  • TABLE 263. Canada 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 264. Canada 14-Alpha Demethylase Inhibitor Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 265. Canada 14-Alpha Demethylase Inhibitor Market Size, by Topical, 2017-2032 (USD Million)
  • TABLE 266. Canada 14-Alpha Demethylase Inhibitor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 267. Canada 14-Alpha Demethylase Inhibitor Market Size, by Dermatological Infections, 2017-2032 (USD Million)
  • TABLE 268. Canada 14-Alpha Demethylase Inhibitor Market Size, by Prophylaxis, 2017-2032 (USD Million)
  • TABLE 269. Canada 14-Alpha Demethylase Inhibitor Market Size, by Systemic Infections, 2017-2032 (USD Million)
  • TABLE 270. Canada 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 271. Mexico 14-Alpha Demethylase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 272. Mexico 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 273. Mexico 14-Alpha Demethylase Inhibitor Market Size, by Imidazoles, 2017-2032 (USD Million)
  • TABLE 274. Mexico 14-Alpha Demethylase Inhibitor Market Size, by Triazoles, 2017-2032 (USD Million)
  • TABLE 275. Mexico 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 276. Mexico 14-Alpha Demethylase Inhibitor Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 277. Mexico 14-Alpha Demethylase Inhibitor Market Size, by Topical, 2017-2032 (USD Million)
  • TABLE 278. Mexico 14-Alpha Demethylase Inhibitor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 279. Mexico 14-Alpha Demethylase Inhibitor Market Size, by Dermatological Infections, 2017-2032 (USD Million)
  • TABLE 280. Mexico 14-Alpha Demethylase Inhibitor Market Size, by Prophylaxis, 2017-2032 (USD Million)
  • TABLE 281. Mexico 14-Alpha Demethylase Inhibitor Market Size, by Systemic Infections, 2017-2032 (USD Million)
  • TABLE 282. Mexico 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 283. Brazil 14-Alpha Demethylase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 284. Brazil 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 285. Brazil 14-Alpha Demethylase Inhibitor Market Size, by Imidazoles, 2017-2032 (USD Million)
  • TABLE 286. Brazil 14-Alpha Demethylase Inhibitor Market Size, by Triazoles, 2017-2032 (USD Million)
  • TABLE 287. Brazil 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 288. Brazil 14-Alpha Demethylase Inhibitor Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 289. Brazil 14-Alpha Demethylase Inhibitor Market Size, by Topical, 2017-2032 (USD Million)
  • TABLE 290. Brazil 14-Alpha Demethylase Inhibitor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 291. Brazil 14-Alpha Demethylase Inhibitor Market Size, by Dermatological Infections, 2017-2032 (USD Million)
  • TABLE 292. Brazil 14-Alpha Demethylase Inhibitor Market Size, by Prophylaxis, 2017-2032 (USD Million)
  • TABLE 293. Brazil 14-Alpha Demethylase Inhibitor Market Size, by Systemic Infections, 2017-2032 (USD Million)
  • TABLE 294. Brazil 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 295. United Kingdom 14-Alpha Demethylase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 296. United Kingdom 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 297. United Kingdom 14-Alpha Demethylase Inhibitor Market Size, by Imidazoles, 2017-2032 (USD Million)
  • TABLE 298. United Kingdom 14-Alpha Demethylase Inhibitor Market Size, by Triazoles, 2017-2032 (USD Million)
  • TABLE 299. United Kingdom 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 300. United Kingdom 14-Alpha Demethylase Inhibitor Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 301. United Kingdom 14-Alpha Demethylase Inhibitor Market Size, by Topical, 2017-2032 (USD Million)
  • TABLE 302. United Kingdom 14-Alpha Demethylase Inhibitor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 303. United Kingdom 14-Alpha Demethylase Inhibitor Market Size, by Dermatological Infections, 2017-2032 (USD Million)
  • TABLE 304. United Kingdom 14-Alpha Demethylase Inhibitor Market Size, by Prophylaxis, 2017-2032 (USD Million)
  • TABLE 305. United Kingdom 14-Alpha Demethylase Inhibitor Market Size, by Systemic Infections, 2017-2032 (USD Million)
  • TABLE 306. United Kingdom 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 307. Germany 14-Alpha Demethylase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 308. Germany 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 309. Germany 14-Alpha Demethylase Inhibitor Market Size, by Imidazoles, 2017-2032 (USD Million)
  • TABLE 310. Germany 14-Alpha Demethylase Inhibitor Market Size, by Triazoles, 2017-2032 (USD Million)
  • TABLE 311. Germany 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 312. Germany 14-Alpha Demethylase Inhibitor Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 313. Germany 14-Alpha Demethylase Inhibitor Market Size, by Topical, 2017-2032 (USD Million)
  • TABLE 314. Germany 14-Alpha Demethylase Inhibitor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 315. Germany 14-Alpha Demethylase Inhibitor Market Size, by Dermatological Infections, 2017-2032 (USD Million)
  • TABLE 316. Germany 14-Alpha Demethylase Inhibitor Market Size, by Prophylaxis, 2017-2032 (USD Million)
  • TABLE 317. Germany 14-Alpha Demethylase Inhibitor Market Size, by Systemic Infections, 2017-2032 (USD Million)
  • TABLE 318. Germany 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 319. France 14-Alpha Demethylase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 320. France 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 321. France 14-Alpha Demethylase Inhibitor Market Size, by Imidazoles, 2017-2032 (USD Million)
  • TABLE 322. France 14-Alpha Demethylase Inhibitor Market Size, by Triazoles, 2017-2032 (USD Million)
  • TABLE 323. France 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 324. France 14-Alpha Demethylase Inhibitor Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 325. France 14-Alpha Demethylase Inhibitor Market Size, by Topical, 2017-2032 (USD Million)
  • TABLE 326. France 14-Alpha Demethylase Inhibitor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 327. France 14-Alpha Demethylase Inhibitor Market Size, by Dermatological Infections, 2017-2032 (USD Million)
  • TABLE 328. France 14-Alpha Demethylase Inhibitor Market Size, by Prophylaxis, 2017-2032 (USD Million)
  • TABLE 329. France 14-Alpha Demethylase Inhibitor Market Size, by Systemic Infections, 2017-2032 (USD Million)
  • TABLE 330. France 14-Alpha Demethylase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 331. Russia 14-Alpha Demethylase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 332. Russia 14-Alpha Demethylase Inhibitor Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 333. Russia 14-Alpha Demethylase Inhibitor Market Size, by Imidazoles, 2017-2032 (USD Million)
  • TABLE 334. Russia 14-Alpha Demethylase Inhibitor Market Size, by Triazoles, 2017-2032 (USD Million)
  • TABLE 335. Russia 14-Alpha Demethylase Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 336. Russia 14-Alpha Demethylase Inhibitor Market Size, by Oral, 2017-2032 (USD